On September 9, 2026, the first participant was dosed in a Phase 1 trial for GZC8072 — a once-weekly oral peptide GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals.

That announcement, combined with two other oral metabolic drug programs entering human trials in the same week, marks an inflection point in how obesity medicine is being developed.

Injectable therapy remains the efficacy gold standard today. But the oral pipeline is now broad enough, advanced enough, and technically diverse enough to warrant a dedicated tracker. This is that tracker.

We will update it as the field moves.

Why the Oral Pipeline Matters

Injectable GLP-1 therapy works. The efficacy data from STEP, SURMOUNT, and TRIUMPH programs is among the strongest in the history of obesity medicine.

But injectables carry structural limitations that affect access at scale:

Patient preference: A meaningful subset of patients won't initiate or maintain injectable therapy due to needle aversion, lifestyle friction, or cost of cold-chain distribution
Manufacturing complexity: Peptide injectables require specialized manufacturing that creates supply constraints
Cost: Per-unit production cost for peptide injectables is higher than small-molecule oral drugs at comparable scale
Access: Oral therapy can reach patient populations that injectable programs can't — geographic markets with limited cold-chain infrastructure, patients who self-discontinue injections

The Four Platforms in the Race

The oral obesity pipeline isn't a single technology. It's four different technological approaches competing to solve the same problem: getting a metabolically active molecule absorbed through the gut in a clinically meaningful amount.

Platform 1: Oral Small-Molecule GLP-1 Receptor Agonists

Replace the peptide with a pill-sized chemical that activates the same receptor

Platform 2: Oral Peptide GLP-1 Delivery

Deliver the actual GLP-1 peptide orally using novel absorption technology

Platform 3: Oral Small-Molecule Amylin Receptor Agonists

Replace the amylin peptide with a small molecule targeting the amylin/calcitonin receptor

Platform 4: Oral Peptide Amylin Delivery

Deliver the amylin peptide orally — the harder version of Platform 2

The Full Tracker — September 2026

APPROVED / COMMERCIALLY AVAILABLE

Oral Semaglutide (Rybelsus / Ozempic oral)

Developer: Novo Nordisk
Mechanism: Oral GLP-1 peptide with SNAC absorption enhancer
Status: FDA-approved for obesity (Wegovy pill, 25 mg) December 22, 2025; US launch January 2026. OASIS 4: −13.6% at 64 weeks vs −2.2% on placebo (treatment-policy estimand); 16.6% among those who adhered
Dosing requirement: Fasted, ≤4 oz water, 30-minute wait
Launch: US January 2026; Germany September 1, 2026
Evidence grade: A — multiple randomized Phase 3 trials

Orforglipron (Foundayo)

Developer: Eli Lilly
Mechanism: Oral small-molecule GLP-1 receptor agonist (non-peptide)
Status: FDA-approved April 2026 for obesity
Key data: ATTAIN-1: -12.4% body weight at 72 weeks
Dosing requirement: None — any time, with or without food
Evidence grade: A — FDA-approved Phase 3

PHASE 3 / LATE DEVELOPMENT

Aleniglipron

Developer: Structure Therapeutics
Mechanism: Oral small-molecule GLP-1 receptor agonist (once-daily)
Status: Phase 2/3; open-label extension reported September 8, 2026
Key data: -16.2% weight loss at 72 weeks (highest dose, open-label extension); no plateau reached; fewer than 5% discontinued for adverse events; better GI tolerability starting at 2.5 mg
Body composition study: planned later 2026 — watch closely
Evidence grade: B — open-label extension; Phase 3 pending
Source: Structure Therapeutics SEC filing, September 8, 2026

ASC30

Developer: Ascletis
Mechanism: Oral small-molecule GLP-1 receptor agonist
Status: Global Phase 3 (AURORA-1 NCT07743463, AURORA-2 NCT07743450; ~4,600 participants, 72 weeks) — first participant dosed August 30, 2026
Evidence grade: C+ — Phase 3 underway

PHASE 1 / EARLY CLINICAL

GZC8072

Developer: Gan & Lee Pharmaceuticals
Mechanism: Oral peptide GLP-1 receptor agonist (once-weekly design)
Status: Phase 1 initiated September 9, 2026 — first participant dosed
Design: 112 participants; single ascending dose in healthy adults → multiple dose in obesity/overweight
Why it's significant: Unlike oral semaglutide (daily, strict fasting), GZC8072 is designed for once-weekly oral dosing. Most newer oral contenders are small molecules, not peptides. A genuine once-weekly oral peptide would be a meaningful delivery achievement.
Evidence grade: C+ — trial initiation only, no human efficacy data yet
Source: PR Newswire, September 9, 2026

ACCG-2671

Developer: Structure Therapeutics
Mechanism: Oral small-molecule dual amylin/calcitonin receptor agonist (non-peptide)
Status: Phase 1/2a — first human data reported September 8, 2026
Key data: ~6-day half-life; -3.3% mean weight at day 24 in 6 participants at 10 mg dose; no serious AEs; nausea dose-dependent at 5-10 mg
Next steps: Multiple-dose testing underway; combination cohort with injectable GLP-1 planned
Why it's significant: First oral small-molecule amylin program to report human data
Evidence grade: C+/B- — Phase 1, tiny sample, single dose
Source: Structure Therapeutics SEC filing, September 8, 2026

ASC36 Oral Tablet

Developer: Ascletis
Mechanism: Oral amylin receptor peptide agonist (POTENT delivery platform)
Status: U.S. Phase 1 initiated September 8, 2026 after IND clearance; 86 participants with obesity or overweight planned
Key preclinical data: absolute oral bioavailability of 8% (10 mg) and 6% (25 mg) at steady state in nonhuman primates; mean body weight reduced up to 13.2% after seven days of once-daily dosing in nonhuman primates
Why it's significant: Oral bioavailability near zero is the historic barrier for peptide drugs. 6-8% in primates, if it translates to humans, would be a genuine platform breakthrough
Evidence grade: C+ — trial initiation, no human efficacy data
Source: Ascletis PR Newswire, September 8, 2026

PRECLINICAL / DISCOVERY

ASC39

Developer: Ascletis
Mechanism: Oral small-molecule amylin receptor agonist (eloralintide-like)
Status: Presented at ADA 2026, preclinical
Evidence grade: D — preclinical only

Adipose-targeted anti-inflammatory nanotherapy

Developer: Academic (ACS Nano, September 8, 2026)
Mechanism: Nanocarriers delivering glucocorticoid-receptor agonist to adipose-tissue macrophages — weight loss without appetite suppression in preclinical models
Status: Preclinical
Why it matters: Proof-of-concept for targeting adipose inflammation as a distinct obesity mechanism. Not approaching the clinic yet.
Evidence grade: D — preclinical

The Platform Competition

Two parallel races are now running simultaneously:

The GLP-1 Race:

Oral peptide (GZC8072, oral semaglutide) vs. oral small molecule (orforglipron, aleniglipron, ASC30)
Key variables: efficacy, tolerability, dosing frequency, food restrictions, manufacturing cost

The Amylin Race:

Oral peptide (ASC36 oral) vs. oral small molecule (ACCG-2671, ASC39)
Key variables: oral bioavailability (the historic barrier for peptides), receptor selectivity, tolerability at effective doses

And sitting above both: the combination question. Structure is already testing ACCG-2671 in combination with injectable GLP-1. Ascletis has ASC36_35FDC — a once-monthly combo injection of amylin + GLP-1/GIP. The question is whether oral monotherapy reaches the efficacy bar, or whether the winning formula is oral GLP-1 + oral amylin as a fully oral combination.

What to Watch

Near-term milestones:

GZC8072 Phase 1 human PK/safety data — does the once-weekly oral peptide maintain its pharmacokinetics in humans?
ASC36 oral Phase 1 — does the POTENT platform's 6-8% primate bioavailability translate?
Aleniglipron body composition study — is oral GLP-1 weight loss comparable in quality (fat vs. lean) to injectable?
ACCG-2671 multiple-dose data — does the amylin signal hold at repeated dosing?

The question that matters most for GLP-1 2.0: Can oral therapy preserve or improve body composition outcomes compared to injectable? Or does the lower peak exposure of oral delivery reduce the lean mass loss signal? We don't know yet.

When aleniglipron's body composition study reports, that will be a major data point.

→ Follow the pipeline at PeptidesGPT.com/research

Sources:

GZC8072 Phase 1 initiation: Gan & Lee PR Newswire, September 9, 2026
ACCG-2671 Phase 1/2a and aleniglipron 72-week: Structure Therapeutics SEC filing, September 8, 2026
ASC36 oral Phase 1 initiation: Ascletis PR Newswire, September 8, 2026
Orforglipron (Foundayo) FDA approval: Lilly investor release, April 1, 2026; ATTAIN-1 Phase 3
OASIS 4: Wharton S, et al. N Engl J Med. 2025;393:1077–1087. PMID 40934115. DOI 10.1056/NEJMoa2500969.
ASC30 AURORA Phase 3 first dosing: Ascletis PR Newswire, September 2026.

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication or protocol.

The Race to Put GLP-1, Amylin, and Obesity Medicine in a Pill: The Full Oral Metabolic Drug Tracker